# Envafolimab Combined With Chemoradiotherapy and Recombinant Human Endostatin for LA-NPC.

> **NCT06059261** · PHASE2 · RECRUITING · sponsor: **Chongqing University Cancer Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Nasopharyngeal Carcinoma

## Interventions

- **DRUG:** Envafolimab and recombinant human endostatin combined with chemoradiotherapy

## Key facts

- **NCT ID:** NCT06059261
- **Lead sponsor:** Chongqing University Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-09
- **Primary completion:** 2027-02-01
- **Final completion:** 2027-02-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06059261

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06059261, "Envafolimab Combined With Chemoradiotherapy and Recombinant Human Endostatin for LA-NPC.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06059261. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*